You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Medtronic
McKinsey
Express Scripts

Last Updated: March 9, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for GLPG2737

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for GLPG2737?

GLPG2737 is an investigational drug.

There have been 5 clinical trials for GLPG2737. The most recent clinical trial was a Phase 2 trial, which was initiated on November 29th 2017.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Polycystic Kidney, Autosomal Dominant. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].

There are two US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for GLPG2737
TitleSponsorPhase
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Galapagos NVPhase 2
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.Galapagos NVPhase 1
GLPG2737 on Top of Orkambi in Subjects With Cystic FibrosisGalapagos NVPhase 2

See all GLPG2737 clinical trials

Clinical Trial Summary for GLPG2737

Top disease conditions for GLPG2737
Top clinical trial sponsors for GLPG2737

See all GLPG2737 clinical trials

US Patents for GLPG2737

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GLPG2737   Start Trial Compounds, compositions, and methods for modulating CFTR Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
GLPG2737   Start Trial Compounds, compositions, and methods for increasing CFTR activity Proteostasis Therapeutics, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GLPG2737

Drugname Country Document Number Estimated Expiration Related US Patent
GLPG2737 Argentina AR108203 2036-04-07   Start Trial
GLPG2737 Australia AU2017248253 2036-04-07   Start Trial
GLPG2737 Brazil BR112018070747 2036-04-07   Start Trial
GLPG2737 Canada CA3019663 2036-04-07   Start Trial
GLPG2737 China CN109563047 2036-04-07   Start Trial
GLPG2737 European Patent Office EP3440057 2036-04-07   Start Trial
GLPG2737 Israel IL262030 2036-04-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Medtronic
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.